Helixgate https://validator.w3.org/feed/docs/rss2.html Home Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool STAT+: FDA eyes expanding testosterone therapy for libido Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch Biovac gets $108M backing for vaccine factory in South Africa TRACERx MRD Results Showcase ppmSeq’s Ultra-Sensitive ctDNA Detection at AACR UPDATE: Kailera breaks biotech IPO record with $625M debut RFK Jr. defends Makary, claims pharma ‘owns’ Congress and media Novo may have muscle advantage over Lilly in weight-loss race: preprint Funding the Future of European Biotech Trevi raises $150M; Spain and Boston set up biotech fund Replimune cries foul on regulatory flexibility. But many Americans want a stricter FDA 5 notable pharma CEO pay hikes in 2025 STAT+: Cell therapy primed liver transplant patients to avoid organ rejection, small study shows Opinion: Don’t believe headlines saying that vaccine skepticism is widespread Merck’s PD-1/VEGF data star in stacked lineup of AACR ‘26 data reveals Stem Cell Editing Programs the Immune System to Make Own Therapeutic Proteins Kailera nets $625M in one of biotech’s biggest-ever IPOs STAT+: HaloMD’s legal win highlights the difficulty of challenging arbitration decisions Trump taps former public health leader Erica Schwartz to run CDC RFK Jr. defends FDA, Makary following Republican questions Kailera raises $625M IPO in biotech record Intercellular Communication via Condensate Corona-Nanoparticle Complexes STAT+: Kennedy focuses on affordability, combating fraud in Capitol Hill hearing Novartis’ Vas Narasimhan heads to Anthropic’s board; Metsera alum joins Structure as COO Proteins.1 Launches to Develop Single Molecule Protein Amplification Tech for Diagnostics Drug pricing watchdog calls for increased transparency into FDA’s accelerated approval decisions AACR 2026 Chairs Identify Themes and Highlights from the Conference FDA mulls compounding for peptides previously flagged over safety risks STAT+: Researchers behind GLP-1 obesity drugs advance new approach: Drop GLP-1 as a target Cochrane review dismissing amyloid drugs draws immediate backlash FDA moves toward easing restrictions on certain peptides Lilly’s new obesity pill passes heart safety test in diabetes Asgard Therapeutics appoints Dr Wolfram Brugger as CMO  MeiraGTx buys back gene therapy from J&J; Storm brings in $56M Series C Landmark Pancreatic Cancer Trial Highlights Promise of RAS-Targeting Daraxonrasib Blurring the lines of healthcare AI MeiraGTx, spying hope in a failed trial, buys back eye disease gene therapy from J&J Using versus selling lucrative PRVs: Moderna’s cautionary tale MSF says Gilead’s lenacapavir supply ‘not nearly enough’; PolyPeptide’s strategic review Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns Can Europe turn world-class science into world-class scale? RyghtAI launches clinical site search engine to aid drug developers, CROs with trial design Obesity’s explosive growth continues as Q1 deals exceed total 2025 value STAT+: Pharmalittle: We’re reading about a review of Alzheimer’s drugs, FDA interest in compounded peptides, and more Revolution doubles stock offering target to $2B following pancreatic cancer win Novartis CEO joins Anthropic board, embedding AI in the heart of biopharma The mental health parity gap is gaping Lilly’s obesity pill heads for diabetes filing after heart risk trial STAT+: Roche to launch another Elevidys trial, with eyes on European approval